Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Fangazio M, Ladewig E, Gomez K, Garcia-Ibanez L, Kumar R, Teruya-Feldstein J, et al. Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2021;118(22).

Naidoo M, Levine F, Gillot T, Orunmuyi AT, E Olapade-Olaopa O, Ali T, et al. MicroRNA-1205 Regulation of FRYL in Prostate Cancer. Front Cell Dev Biol. 2021;9:647485.

Manohar J, Abedian S, Martini R, Kulm S, Salvatore M, Ho K, et al. Social and Clinical Determinants of COVID-19 Outcomes: Modeling Real-World Data from a Pandemic Epicenter. medRxiv. 2021.

Westblade LF, Magleby R, Trzebucki A, Simon MS, Rajan M, Park J, et al. Reply to Rhoads, et al. Clin Infect Dis. 2021;72(10):e687.

Itkonen HM, Loda M, Mills IG. O-GlcNAc Transferase - An Auxiliary Factor or a Full-blown Oncogene? Mol Cancer Res. 2021;19(4):555-564.

Karafin MS, Becker JL, Berg M, DeSimone RA, Draper NL, Hudgins J, et al. Heterogeneity in Approaches for Switching From Universal to Patient ABO Type-Specific Blood Components During Massive Hemorrhage: An International Survey and Review of the Literature. Arch Pathol Lab Med. 2021.

Iannello A, Vitale N, Coma S, Arruga F, Chadburn A, Di Napoli A, et al. Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models. Blood. 2021;137(24):3378-3389.

Shigeta S, Lui GY, Shaw R, Moser R, Gurley KE, Durenberger G, et al. Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma. Mol Cancer Ther. 2021;20(4):691-703.

Yang HS, Shemesh A, Li J, Xie T, Apple FS, Williams JA, et al. No increase in the incidence of cardiac troponin I concentration above the 99th percentile by Siemens Centaur high-sensitivity compared to the contemporary assay. Clin Biochem. 2021;89:77-80.

Mosquera MJ, Kim S, Bareja R, Fang Z, Cai S, Pan H, et al. Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors. Adv Mater. 2021:e2100096.